Published in Mayo Clin Proc on February 01, 2007
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res (2012) 1.28
Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis (2007) 1.25
The emerging roles of PAF acetylhydrolase. J Lipid Res (2008) 1.22
Life course socioeconomic position is associated with inflammatory markers: the Framingham Offspring Study. Soc Sci Med (2010) 1.21
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation (2010) 1.14
Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol (2010) 1.11
HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res (2008) 1.09
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Vascular effects of the red blood cell storage lesion. Hematology Am Soc Hematol Educ Program (2011) 1.01
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One (2011) 0.94
Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis (2008) 0.93
Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res (2009) 0.89
Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis (2010) 0.88
Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem (2013) 0.88
Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis (2014) 0.87
Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab (2010) 0.86
The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr (2008) 0.84
Biomarkers of atherosclerosis: clinical applications. Curr Cardiol Rep (2008) 0.83
Role of secretory phospholipase A₂ in women with metabolic syndrome. Indian J Med Res (2013) 0.83
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimers Res Ther (2012) 0.81
Taiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores. Yonsei Med J (2011) 0.80
White blood cell count predicts all-cause mortality in patients with suspected peripheral arterial disease. Am J Med (2009) 0.80
Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia. J Lipid Res (2010) 0.80
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection. HIV Med (2014) 0.80
Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther (2011) 0.79
Racial variation in lipoprotein-associated phospholipase A₂ in older adults. BMC Cardiovasc Disord (2011) 0.79
Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population. Mamm Genome (2015) 0.79
Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. J Res Med Sci (2011) 0.78
Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis (2014) 0.78
Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Curr Atheroscler Rep (2010) 0.78
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis (2008) 0.77
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis. N Am J Med Sci (Boston) (2011) 0.76
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. J Clin Lipidol (2014) 0.76
Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies. Auto Immun Highlights (2017) 0.75
Cardiovascular risk assessment in patients with rheumatoid arthritis: a correlative study of noninvasive arterial health testing. Clin Rheumatol (2016) 0.75
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. J Am Heart Assoc (2015) 0.75
Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res (2011) 0.75
Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for "prime time". Mayo Clin Proc (2007) 0.75
Lp-PLA2 Inhibition-The Atherosclerosis Panacea? Pharmaceuticals (Basel) (2010) 0.75
Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus. Indian J Med Res (2015) 0.75
Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease. Mayo Clin Proc (2007) 0.75
Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke. Turk J Emerg Med (2016) 0.75
Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels. J Am Heart Assoc (2017) 0.75
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS One (2017) 0.75
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Internet-based learning in the health professions: a meta-analysis. JAMA (2008) 8.74
Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet (2006) 8.61
Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med (2015) 8.61
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol (2007) 7.79
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid (2011) 7.17
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 7.15
Effect of altitude on leptin levels, does it go up or down? J Appl Physiol (1985) (2008) 6.68
Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med (2007) 6.68
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 6.48
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med (2011) 5.82
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA (2003) 5.39
We need minimally disruptive medicine. BMJ (2009) 5.35
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (2008) 5.16
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.90
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation (2002) 4.77
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 4.73
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.68
Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ (2004) 4.53
The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol (2002) 4.19
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2009) 4.04
Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2012) 4.02
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med (2005) 3.84
Association of atrial fibrillation and obstructive sleep apnea. Circulation (2004) 3.81
The idolatry of the surrogate. BMJ (2011) 3.81
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 3.80
A new 'mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol (2008) 3.75
Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology (2013) 3.70
Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci (2009) 3.68
Instructional design variations in internet-based learning for health professions education: a systematic review and meta-analysis. Acad Med (2010) 3.56
GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol (2011) 3.54
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract (2011) 3.40
Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab (2010) 3.40
Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity. Heart (2012) 3.36
The scoring of respiratory events in sleep: reliability and validity. J Clin Sleep Med (2007) 3.07
Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension (2005) 3.07
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ (2013) 3.05
Assessing adiposity: a scientific statement from the American Heart Association. Circulation (2011) 3.00
Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc (2013) 3.00
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol (2007) 2.99
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation (2002) 2.93
Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2007) 2.93
Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J (2007) 2.86
Plasma homocysteine in obstructive sleep apnoea. Eur Heart J (2004) 2.85
Endurance exercise as a countermeasure for aging. Diabetes (2008) 2.83
Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med (2007) 2.82
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77
Obstructive sleep apnea. Ann Intern Med (2005) 2.75
Sex differences in arterial stiffness and ventricular-arterial interactions. J Am Coll Cardiol (2012) 2.74
Investing in deliberation: a definition and classification of decision support interventions for people facing difficult health decisions. Med Decis Making (2010) 2.73
Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J (2009) 2.71
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension (2011) 2.68
Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc (2007) 2.63
Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol (2013) 2.61
Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory. Ann Fam Med (2011) 2.59
An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol (2004) 2.58
Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab (2008) 2.52
Let the patient revolution begin. BMJ (2013) 2.50
Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol (2011) 2.50
Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet (2011) 2.48
GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol (2013) 2.46
Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials. J Clin Endocrinol Metab (2008) 2.45
Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J (2007) 2.38
What do we mean by web-based learning? A systematic review of the variability of interventions. Med Educ (2010) 2.38
Author self-citation in the diabetes literature. CMAJ (2004) 2.38
The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis (2006) 2.37
Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA (2013) 2.31
Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med (2015) 2.31
Sleep-disordered breathing and cardiovascular disease. Circulation (2003) 2.30
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J (2004) 2.29
Survival in patients with poorly compressible leg arteries. J Am Coll Cardiol (2012) 2.25
The national cholesterol education program diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial. Arch Intern Med (2004) 2.24
Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab (2008) 2.21
Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med (2007) 2.21